Cardiology

Afib
  • AFFIRM. A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. NEJM 2002; 347(23): 1825-33.
  • AFFIRM. A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Atrial Fibrillation. NEJM 2002; 347(23): 1834-40.
  • RACE. Lenient versus Strict Rate Control in Patients with Atrial Fibrillation. NEJM 2010; 362(15): 1363-73.
  • RE-LY. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. NEJM 2009; 361(12): 1139-51.
CAD
  • AIM-HIGH. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. NEJM 2011; 365: 2255-67.
  • EPHESUS.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. NEJM 2003; 348:1309 –1321.

  • HACA. Mild Therapeutic Hypothermia to Improve the Neurologic Outcome after Cardiac Arrest. NEJM 2002; 346(8): 549-56.
  • JUPITER. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. NEJM 2008; 359(21): 2195-207.
  • MIRACL. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes. JAMA 2001; 285: 1711-18.
  • REACH. B-Blocker Use and Clinical Outcomes in Stable Outpatients with and without Coronary Artery Disease. JAMA 2012; 308(13): 1340-49.
  • OAT. Coronary Intervention for Persistent Occlusion after Myocardial Infarction. NEJM; 355(23): 2395-407.
  • PROVE-IT. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. NEJM 2; 305(15): 1495-504.
  • SYNTAX. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. NEJM 2009; 360(10):961-72.
CHF
  • A-HEFT. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. NEJM 2004; 351(20): 2049-57.
  • CARE-HF. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. NEJM 2005; 352(15): 1539-49.
  • COMPANION. Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure. NEJM 350(21): 2140-50.
  • CONSENSUS. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. NEJM 1987; 316(23): 1429-35.
  • HOPE. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. NEJM 200; 342(3): 145-53.
  • MADIT-CRT. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. NEJM 2009; 361(14): 1329-38.
  • RALES. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. NEJM 1999; 341(10): 1709-17.
  • RAFT. Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure. NEJM 2010; 363(24): 2385-95.
  • SCD-HEFT. Amiodarone or an Implantable Cardioverter-Defibrillator for Congestive Heart Failure. 2005; 352(3): 225-37.
  • STITCH. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. NEJM 2011; 364(17): 1607-16.
  • VHEFT I. Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. NEJM 1986; 314(24): 1547-52.
  • VHEFT II. A Comparison of Enalapril with Hydralazine-Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure. NEJM 1991; 325(5): 303-10.

HTN
  • ALLHAT. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. JAMA 2002; 288: 2981-97.
  • ALLHAT. Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril. JAMA 2007; 293(13): 15915-1608.
  • ALLHAT. Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia. Arch Intern Med 2005; 165: 1401-1409.
  • ALLHAT. Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Hypertens 1996; 9: 342-360.
  • HOT. Effects of Intensive Blood-Pressure Lowering and Low-Dose Aspirin in Patients with Hypertension: Principal Results of the Hypertension Optimal Treatment (HOT) Randomised Trial. Lancet 1998; 351: 1755-62.
  • HYVET. Treatment of Hypertension in Patients 80 Years of Age or Older. NEJM 2008; 358(8): 1887-98.